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Abstract
Flavivirus envelope protein (E) mediates membrane fusion and viral entry from endosomes. A low-pH induced, dimer-to-
trimer rearrangement and reconfiguration of the membrane-proximal ‘‘stem’’ of the E ectodomain draw together the viral
and cellular membranes. We found stem-derived peptides from dengue virus (DV) bind stem-less E trimer and mimic the
stem-reconfiguration step in the fusion pathway. We adapted this experiment as a high-throughput screen for small
molecules that block peptide binding and thus may inhibit viral entry. A compound identified in this screen, 1662G07, and a
number of its analogs reversibly inhibit DV infectivity. They do so by binding the prefusion, dimeric E on the virion surface,
before adsorption to a cell. They also block viral fusion with liposomes. Structure-activity relationship studies have led to
analogs with submicromolar IC90s against DV2, and certain analogs are active against DV serotypes 1,2, and 4. The
compounds do not inhibit the closely related Kunjin virus. We propose that they bind in a previously identified, E-protein
pocket, exposed on the virion surface and although this pocket is closed in the postfusion trimer, its mouth is fully
accessible. Examination of the E-trimer coordinates (PDB 1OK8) shows that conformational fluctuations around the hinge
could open the pocket without dissociating the trimer or otherwise generating molecular collisions. We propose that
compounds such as 1662G07 trap the sE trimer in a ‘‘pocket-open’’ state, which has lost affinity for the stem peptide and
cannot support the final ‘‘zipping up’’ of the stem.
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Introduction
Enveloped viruses penetrate into the cytosol of their target cell
by fusion of viral and cellular membranes [1,2]. Flaviviruses, such
as dengue, penetrate from endosomes, following uptake by
clathrin-mediated endocytosis [3,4]. At endosomal pH, proton
binding by their envelope protein, E, triggers a fusion-promoting
conformation change [5,6].
The flavivirus envelope fusion protein, E, forms a well-ordered
lattice of 90 dimers on the surface of a mature, infectious virus
particle [2,7]. Crystal structures of soluble forms of E (‘‘sE’’), which
include the first ,395 of ,445 ectodomain residues but lack a
conserved, membrane-proximal ‘‘stem’’ region, have contributed to
moleculardescriptionsofflavivirusfusion[8–12].Thethreedomains
(DI–III) ofthe Eproteinreorient withrespectto oneotherduring the
fusion-promoting conformational transition, which includes dissoci-
ation of the prefusion dimer and reconfiguration of the subunits into
trimers [2]. At an intermediate stage a hydrophobic ‘‘fusion loop’’ at
one end of the extended E subunit inserts into the outer leaflet of the
target bilayer [2,13]. The driving force for pinching the two
membranes together appears to come from contacts made by
domain III, as it folds back against domain I, and by the stem, as it
‘‘zips’’ up along adjacent domain II monomers [1,2].
Molecular understanding of the fusion pathway and the proteins
involved has enabled discovery of small-molecule and peptide
inhibitors that target intermediates in these fusion-inducing
rearrangements. The best-known example of the latter type of
entry inhibitor is T-20/enfuvirtide, a peptide used to treat HIV-1
infection [14–17]. The T-20 peptide interferes with a late stage in
the fusion-inducing conformational transition of HIV-1 gp41.
Certain small molecules block HIV-1 fusion by a similar
mechanism, binding in a conserved pocket on the gp41 inner
core [18]. Inhibitors that target the fusion glycoprotein, F1, of
respiratory syncytial virus (RSV) also prevent infection by blocking
a conformational transition [19,20].
Targeting the HIV-1 and RSV glycoproteins is possible,
because fusion occurs at the plasma membrane, where exposure
of the relevant fusion intermediates allows straightforward access
to the specific inhibitors. For viruses such as flaviviruses that fuse
from endosomal compartments, however, targeting an intermedi-
ate of the rearranging fusion protein requires concentrating the
inhibitor within the endosome, as its potential binding sites are not
available until reduced pH has induced their exposure.
Kielian and co-workers have reported reconstitution of an sE
trimer for both alpha- and flavivirus envelopes, suggesting that one
might use reconstitution strategies to identify inhibitors that block
steps in fusion [21,22]. We found recently that we could target a
fusion intermediate of dengue virus E with peptides derived from
its ectodomain stem [23,24]. These peptides bind the postfusion
form of DV2 sE trimer, mimicking late steps in stem rearrange-
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modification with membrane targeting sequences increases their
inhibitory strength [23]. A series of experiments support a two-step
mechanism, in which a reversible, non-specific interaction with the
viral membrane brings virion-associated peptides into the low-pH
endosome, where full exposure of the peptide site on the E-protein
conformational intermediate leads to tight, specific binding, which
interfere with the final ‘‘zipping’’ of the stem [24].
Can small molecules also inhibit this step in the fusion pathway?
We have adapted the assay we used to study interaction of stem-
derived peptides with stem-less sE trimer, to screen for small-
molecule inhibitors that target this fusion intermediate. We have
identified compounds that compete for stem peptide association,
and we show that they reversibly inhibit DV infectivity. We further
show, using model liposomes, that these molecules specifically
block viral fusion. They appear to bind the virion before
adsorption to cells, by interacting with the prefusion, dimeric E
protein, possibly in a previously identified, hydrophobic pocket.
This association presumably permits their virus-associated transfer
into endosomes. Limited structure-activity relationship studies
have yielded compounds that inhibit DV2 (NGC isolate) with
IC90,1 mM. Our competition screen has thus identified a group
of potent, small-molecule inhibitors of DV entry validating
experimental screens for small molecules that block viral entry
from internal compartments.
Results
High-throughput screen (HTS) for DV fusion inhibitors
We have described a fluorescence polarization (FP) assay to
identify stem-derived peptides that bind the trimeric postfusion
conformer of DV2 sE [24]. We found peptides from the C-
terminal stem region that bind tightly to this proposed fusion
intermediate. With one such peptide, DV2
419–447, tagged at its N-
terminus with FITC, we adapted the FP assay to screen for small
molecules that compete for binding to trimeric sE (Figure 1). We
screened ,30,000 compounds in a 384-well format and found
several that were active, as measured by a reduction in the
fluorescence polarization signal. We chose to pursue further work
on one such ‘‘hit’’, 1662G07 (Figure 2), for which several
structurally similar compounds were commercially available.
We tested a set of related compounds, both from the screening
libraries and from commercial vendors, to obtain preliminary
structure activity relationships (SAR). Several modifications to the
parental scaffold affected competition with peptide (Table S1).
Modification or removal of the nitrile moiety (R1 position)
impaired or abolished activity. Removal of the halogen in the m-
position on the R2 (as phenyl) decreased competition; addition of
strongly electron withdrawing groups (either trifluoro- or trifluor-
omethoxy) in the o-o rm-positions increased it. A thiophene at R3
was equivalent to the furan in 1662G07, but a cyclopropane in
that position eliminated competition with peptide.
Directed synthesis of 1662G07 analogs
From preliminary SAR analysis with commercial analogs
described above, we chose to synthesize two series of compounds
based on the parental scaffold. Series 3-148, 3-149 and 3-151
varied the R2 position while the 3-110 varied at the R3 positions.
(Figures 2 and 4, Tables S2 and S3). Among the 51 compounds
from these series, we found that sixteen competed with stem-
derived peptide for binding to the DV2 sE trimer. Strongly
electron withdrawing groups in the o-, m-,o rp- positions on R2 (as
phenyl) enhanced activity; substitution with methyl or methoxy-
methyl groups at these positions yielded inactive compounds.
Some larger, heterocyclic rings impaired activity (Figures 2 and 4.
Tables S2 and S3).
1662G07 analogs inhibit DV2 infectivity
Do these small molecules, identified in a screen for binding to a
late-stage fusion intermediate, inhibit DV2 viral infectivity? We
used a standard plaque forming assay to test the effect of the
analogs from the 3-148, 3-149, 3-151 and 3-110 series at a single
concentration on growth of DV2 NGC. The virus inoculum was
Figure 1. Schematic of high-throughput screening platform.
DV2 sE3 with one monomer colored by domain: DI (red), DII (yellow)
and DIII (blue). Stem peptide DV2
419–447, with FITC at its N-terminus, is
represented as a cylinder, conjugated at its N-terminus with FITC.
Addition of small molecules from screening libraries either affect (active




Fusion of viral and cellular membranes is necessary to
establish infection by an enveloped virus. This process is
facilitated by rearrangement of protein(s) present on the
virion surface in response to molecular cues from the
compartment from which fusion occurs, such as low pH of
an endosome. Dengue virus is an enveloped virus in the
flavivirus family; its ‘‘E’’ (for envelope) protein is the fusion
mediator. We previously showed that peptides derived
from the membrane proximal ‘‘stem’’ of the E protein bind
a form of E that represents a late-stage fusion intermedi-
ate. We used this assay to screen for small-molecule
inhibitors that compete for stem-peptide association with
E. We describe one such inhibitor and its analogs that
block viral fusion. These inhibitors also block infectivity if
added to dengue virus before infection. Withdrawing the
inhibitor before fusion reverses the blockage. We propose
that these small molecules bind a hydrophobic pocket on
the virion surface and that the virus carries them into the
endosome, where they prevent viral fusion by stabilizing
an intermediate conformation of the E protein that cannot
complete the fusion-promoting conformational change.
Identification of these fusion inhibitors shows that viral
entry is a possible target for anti-flavivirus drugs.
Dengue-Virus Fusion Inhibitiors
PLoS Pathogens | www.plospathogens.org 2 April 2012 | Volume 8 | Issue 4 | e1002627preincubated with compound for 15 minutes and then adsorbed to
BHK-21 cells, at a multiplicity of infection (MOI) of 1, for 1 hour
at 37uC. Supernatants were harvested after 24 hours and titred by
standard plaque assay [23]. A subset of the compounds from both
series reduced DV2 infectivity (Figures 2 and 4, Tables S2 and S3).
Compounds were inactive against vesicular stomatitis virus, an
unrelated enveloped virus and were noncytotoxic at the concen-
trations tested (Figure S7, Figures 2 and 4, Tables S1, S2 and S3).
Comparison of the activity profiles from the 3-148, 3-149 and 3-
151 series in the peptide-competition and viral infectivity assays
revealed a clear concordance between active compounds in one
assay and actives compounds in the other (Figure 3). The
likelihood that this degree of concordance could be random is
less than 10
24.
Compounds in the 3-110 series were particularly active against
DV2. We therefore tested this series at a single concentration
(5 mM) against isolates from the other three dengue serotypes:
DV1 WP74, DV3 THD 3 and DV4 TVP360. The compounds of
series 3-110 inhibit DV1, 3 and 4 infectivity to varying degrees
(Figures 4 and S1 and Table S3). DV3 was particularly insensitive
to inhibition, as we had also found when testing its response to
stem-derived peptides. From this initial screen, we looked more
closely at three analogs that appeared to have the strongest
antiviral effect, 3-110-5, 3-110-14 and 3-110-22. We examined
their inhibition of DV2 and DV4 viruses to determine IC90s. As
seen in Figure 4 these compounds had strong antiviral activity
against DV2 and DV4, with IC90s in submicromolar and
micromolar ranges, respectively. At the same concentration used
with the DV serotypes, none of the compounds had detectable
activity against Kunjin, a subtype of West Nile virus (Figure S2);
the analogs most potent for inhibiting dengue, 3-110-5, 3-110-14
and 3-110-22, had no effect on Kunjin, even at 20 mM.
The small-molecule inhibitors were selected in a screen that
detects formation of an E-protein conformation adopted only after
a virion has arrived in the low-pH environment of an endosome –
an intracellular compartment presumably inaccessible to the free
compounds. A series of order-of-addition experiments using the 3-
148, 3-149 and 3-110 series show that to have a significant
Figure 2. Biochemical, cytotoxicity and antiviral summary of 1662G07 select compounds from the 3-148, 149 and 151 series.
doi:10.1371/journal.ppat.1002627.g002
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with the viral inoculum before adsorption to cells (Figure 5). We
observed the same level of inhibition using a direct plaque assay as
a readout (Figure S8). When compound and virus inoculum were
added to cells at the same time, we detected an approximately
tenfold drop in viral titre compared with the DMSO control for
compounds in the 3-110 series and little or no effect for
compounds in the 3-148 and 3-149 series. Postinfection treatment
of cells with compound one hour after initial adsorption of virus
did not reduce viral titre, nor did pretreatment of cells for one
hour before virus adsorption (Figure 5 and data not shown). These
results imply a direct association of compound and virion before
endocytosis of the virus.
Inhibition of fusion
To detect DV2 fusion with liposomes, we used the content-
mixing assay we previously applied to characterize peptide
inhibitors of DV [24]. Selected compounds from the 3-148, 3-
149 and 3-110 series were incubated for 15 minutes at 37uC with
virus, which was then added to trypsin-loaded liposomes. We
adjusted the pH of the medium to ,5.5 for 10 minutes, back-
neutralized the samples, and incubated for an additional
45 minutes at 37uC to allow trypsin to act. Digestion of the viral
core protein, which would have been exposed to protease only
after fusion of virions with liposomes, was assessed by SDS-PAGE
and immunoblotting. Protection of the core protein from
proteolysis with retention of the envelope protein indicated an
effective fusion inhibitor. A subset of the compounds we tested
specifically blocked content mixing of virus with trypsin-loaded
liposomes (Figure 6). We used stem peptide DV2
419–447, previously
shown to inhibit fusion, as a positive control.
Interaction of inhibitory compounds with a DI/DII
fragment of E
The assay we used to find inhibitory compounds detects an
interaction with trimeric E, which forms on virions only after
Figure 3. Activity profiles of selected compounds in competition FP and PFA assays. (A) Representative FP titration curves of active
analogs: 3-148-1, 3-148-2 and 3-149-3 and inactive analogs: 3-151-2, 3-151-3 and 3-151-6 and their competition with the interaction between stem
peptide and sE3. (B) Activities in the two assays for all compounds in the SAR series which varied at R2 (as phenyl). Table 1 and Supplementary Table 2
give the chemical structures of all compounds in this list. (C) Summary of the numbers of active and inactive compounds in each of the two assays.
The likelihood that this degree of concordance could result from random pairing of unrelated activities is less than 10
24. Only 9 of the 31 compounds
had activities within the range of achievable concentrations, making a quantitative correlation of those activities uninformative, particularly in few of
other sources of error such as nonspecific binding to cell surfaces in the case of the infectivity assay and limited solubility of some compounds in the
case of both assays.
doi:10.1371/journal.ppat.1002627.g003
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bind virions at pH 7. Thus, the inhibitors can associate with both
the pre- and postfusion E-protein conformers. Unless their binding
site is at an interface between adjacent subunits in one of the two
conformational states, we expect the compounds also to bind a
monomeric form of E. We expressed and purified DI/DII, a
soluble, monomeric fragment of E comprising only the first two
domains (Figure S3) and showed by surface plasmon resonance
(SPR) that the inhibitory small molecules from both series indeed
bind directly and reversibly to DI/DII (Figure 7). Control
compounds, which do not inhibit viral infectivity and do not
compete for peptide binding to trimeric sE, do not bind DI/DII.
Reversibility of binding to virions
To rule out the possibility that the small molecules inactivate
virions nonspecifically, we tested whether addition of DV2 DI/DII
to an inoculum preincubated with a small-molecule inhibitor could
restore infectivity. We incubated a virus inoculum for 10 minutes
with selected compounds from the 3-148, 3-139 and 3-110 series at
inhibitory concentrations and then added DI/DII in molar excess.
Exogenous DI/DII indeed reversed the small-molecule inhibition
(Figure 8). DV2 DI/DII alone did not affect viral titre. WNV DI/
DII did not restore infectivity in the presence of these compounds
(Figure S9), consistent with their failure to inhibit Kunjin virus.
Discussion
We have shown that 1662G07 and it analogs inhibit growth of
DV2 and that they block low-pH triggered fusion of virus with
liposomes. We identified the parent compound, 1662G07, in a high-
throughput screen that detected competition by active molecules
with binding to trimeric sE of a fluorescein-tagged, stem-derived
peptide. We designed this assay to represent the final step(s) in the
low-pH triggered, E-protein conformational change – the process
that induces penetration from endosomes through fusion of viral and
endosomal membranes. Nonetheless, the inhibitory activity of these
small molecules depends on binding to a virion before the virus
encounters a cell, indicating that the compounds can also associate
with E in its dimeric, pre-fusion conformation. Indeed, they bind in
solution to a monomeric, DI/DII fragment of E, and addition of this
fragment to an inoculum preincubated with one of the compounds
restores infectivity, presumably by sequestering the inhibitor.
How can small molecules that bind the prefusion E dimer and
the DI/DII fragment also block association of a stem-derived
peptide with the sE trimer? From the known structures of sE
dimers (prefusion) [9] and trimers (postfusion) [25] and from
accurate docking of the former into subnanometer-resolution
cryoEM reconstructions of virions [26], we can propose both an
answer to this question and a model for the mechanism of action
of the small-molecule inhibitors we have studied. The activity of
these molecules in an assay for infectivity correlates well with their
capacity to compete with a stem-derived peptide for binding to sE
trimer. The most straightforward explanation for this correlation is
that the compounds bind at a site accessible on both prefusion and
postfusion E conformers. The most obvious site on E for small-
molecule binding is a pocket, adjacent to the hinge between
domains I and II, which accepts a b-octyl-glucoside (b-OG)
molecule when sE dimers are crystallized in the presence of the
detergent. This pocket closes down in the trimer conformation
seen in the crystal structure, and the closed pocket is incompatible
with occupancy by a bulky ligand (e.g., 1662G07). A dimer-to-
trimer conformational transition will then require expulsion of the
ligand, imposing a barrier to completion of the fusion process. For
this reason, several groups have used in silico screens to find
potential pocket-binding compounds, and in at least two cases, the
results of those screens have yielded active inhibitors [27–31]. It
Figure 4. Biochemical, cytotoxicity and antiviral summary of selected compounds from the 3-110 series.
doi:10.1371/journal.ppat.1002627.g004
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PLoS Pathogens | www.plospathogens.org 5 April 2012 | Volume 8 | Issue 4 | e1002627Figure 5. Effect of order-of-addition on small-molecule inhibition. (A) Comparison of o-, m-, and p-OCF3 and m-, di-m- and p-CF3 substitution
from the 3-148 and 3-149 series (B) Comparison of compounds from the 3-110 series. Preincubation: addition of 1662G07 analogs to inoculum 159
before adsorption to cells. Coinfection: addition of analogs at the time of adsorption. Postinfection: addition of analogs one hour after adsorptiono f
virus. In all cases, cells were washed with PBS before adding compounds. Supernatants were harvested after 24 hours and viral titres determined by
standard plaque forming assay (done in duplicate). Compounds from (A) and (B) were used at 15 and 5 mM, respectively. DV2
419–447 stem peptide at
1 mM was used as a control.
doi:10.1371/journal.ppat.1002627.g005
Figure 6. Inhibition of viral fusion with liposomes. Effect on content mixing of preincubating virus with 1662G07 analogs. Virus and analogs 3-
148-1, 3-149-15, 3-110-5 and 3-110-22 (all at 50 mM) were incubated with liposomes encapsulating trypsin and acidified to pH=5.5. Following back-
neutralization and incubation for 1 hr at 37 C, samples were prepared for SDS-PAGE and immunoblotted with aC and aE antibody. Fusion leads to
exposure of core protein to trypsin and loss of the corresponding band but retention of the envelope protein band. DV2
419–447 stem peptide, at
1 mM, was used as a positive control.
doi:10.1371/journal.ppat.1002627.g006
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in this way indeed bind in the pocket as predicted. One of those
computational screens used the Maybridge library for its search,
and one of two active inhibitors identified is related to 1662G07,
including most of the scaffold in Figure 2 [27]. That compound
was not represented, however, in the version of the Maybridge
library we used in our experimental screen. We have docked
several of our compounds, using the GLIDE program [32]. We
obtain fits consistent with the crystallographically observed
interactions of b-OG (Figure S6).
Although the b-OG pocket is closed in the trimer, its mouth is fully
accessible. Examination of the E-trimer coordinates (PDB 1OK8)
shows that conformational fluctuations around the hinge could open
the pocket without dissociating the trimer or otherwise generating
molecular collisions (Figure 9). We suggest that compounds such as
1662G07 inhibit peptide binding by trapping the sE trimer in a
‘‘pocket-open’’ state, which has lost affinity for the stem peptide and
cannot support the final ‘‘zipping up’’ of the stem (Figure 9). Binding
of a compound in the b-OG pocket can explain how it accompanies
virions into endosomes. Then, even if structural rearrangements of
the E protein as it transitions at low pH from dimer to trimer expel
the compound from the pocket, it would still remain at relatively high
concentration in the endosomal space and be able to rebind rapidly.
Effective inhibition wouldsimply require that the rate of rebinding be
higher than the rate at which the stem zips up along domain II.
One potent inhibitor of infectivity for all four dengue serotypes,
compound 3-110-22, failed to inhibit stem-peptide binding in the
competition assay (Figure 4). A likely explanation is that
modification of the parental scaffold to produce 3-110-22 gave a
compound with high affinity for the b-OG pocket in the E dimer,
but lower affinity for the pocket-open state of the E trimer. The
region that surrounds the mouth of the pocket differs in the two
conformations, because of the fold-back of domain III (Figure 9),
and 3-110-22 has a bulky substituent group. It appears that
compound 3-110-22 indeed binds tightly to the E dimer, because
unlike a number of others, it blocks the dimer-to trimer-transition
of sE in vitro (Figure S4).
There are less likely alternative explanations for the inhibitory
action of the compounds we have studied. One postulates a
binding site, other than the b-OG pocket, that is present on
monomeric DI/DII, on dimeric sE and on trimeric sE and that
overlaps the peptide site on the trimer; another is a multi-site and
multi-step mechanism. There is no evident candidate site for the
former mechanism. The latter requires correlated affinities and
properties of multiple sites. We therefore suggest that our
peptide-competition, high-throughput screen has identified a
large set of molecules that bind the b-OG pocket and that we
have devised a useful assay for pocket-binding inhibitors,
potentially applicable to any flavivirus for which one can
prepare a stable, trimeric sE.
Figure 7. Interaction of 1662G07 analogs with DI/DII. DI/DII was immobilized on a CM5 sensorchip. Analogs 3-148-1, 3-149-3, 3-149-14, 3-151-
2, 3-151-2, 3-151-5, 3-151-4, 3-110-5, 3-110-14 and 3-110-22 were passed over the DI/DII surface at 10, 20 and 40 mM. Background for nonspecific
binding to the chip surface was corrected for by passing the analogs over a protein-free channel. All measurements carried out in duplicate.
doi:10.1371/journal.ppat.1002627.g007
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Peptide synthesis
Stem peptide 419–447, with the DV2 NGC sequence and an
RGKGR solubility tag appended at its C-terminus, was synthe-
sized using standard Fmoc chemistry on an ABI 431 Peptide
Synthesizers at the Tufts University Core Facility (Boston, MA),
purified using reverse phase HPLC, and analyzed by mass
spectrometry. Fluorescein-isothiocyanate (FITC) was conjugated
to the N-terminus of the peptide through a b-alanine linker.
Liposomes
Liposomes [made with 1-palmitoyl-2-oleoyl-sn-glycero-3-phos-
phocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phos-
phoethanolamine (POPE) (Avanti Polar Lipids) and cholesterol
(Sigma-Aldrich) in a 1:1:2 molar ratio in TAN buffer (20 mM
triethanolamine, 100 mM NaCl, pH 8.0)] were prepared by
freeze-thaw extrusion through a 0.2 m filter as described previously
[24].
Preparation of sE trimers
The postfusion sE trimer was produced as described [24].
Purified sE (Hawai’i Biotech) was incubated at 37uC in the
presence of liposomes of the composition described above and
acidified with MES buffer. Liposomes were solubilized with n-
octyl-b-D-glucoside (b-OG) and n-undecyl-maltopyranoside
(UDM). The solution was applied to a monoS column (GE
Healthcare); sE trimer was eluted with a 2 M NaCl step gradient
and further purified by size-exclusion chromatography on Super-
dex 200 (GE Healthcare). Protein was dialyzed extensively using a
50-KDa molecular-weight cutoff membrane (Spectrapor).
Synthesis of 1662G07 analogs
Synthetic analogs of 1662G07 were prepared as described in
Text S1 [33].
High-throughput screening
All screens were preformed at the NSRB at Harvard Medical
School. Binding experiments were carried out in Corning, low-
Figure 8. Reversibility of antiviral effect. Viral inocula were
preincubated with 1662G07 analogs from the (A) 3-148 and 3-149 and
(B) 3-110 series for 109 at 37uC. DI/DII was then added in molar excess
and the incubation continued for an additional 159. Each inoculum was
added to cells, and supernatants were harvested 24 hrs later. An
inoculum preincubated with DI/DII alone at the same molar excess
showed no loss in viral titre.
doi:10.1371/journal.ppat.1002627.g008
Figure 9. Proposed mechanism of action of small-molecule inhibitors and postulated equilibrium between two conformations of
the sE trimer. In the ‘‘pocket-open’’, inhibitor-stabilized conformation (right image), the stem-binding groove is absent and the final fusion-inducing
step in the conformational change cannot occur. Moreover, sE in this pocket-open conformation would not bind stem-derived peptides. Domains I, II
and III are in red, yellow and blue, respectively. All images created with PyMol.
doi:10.1371/journal.ppat.1002627.g009
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EnVisions instrument (excitation wavelength, 485 nm; emission
wavelength, 535 nm). sE trimer was added to each well at
0.150 mMi n3 0mL of TAN buffer. 0.1 mL of compound was
transferred to each well and incubated at room temperature for
1 hr before the addition of DV2
419–447 at a final concentration of
20 nM. After a 3-hour incubation, plates were read and
fluorescence polarization measurements recorded. The original
hit described in this paper came from the Maybridge 5 screening
library at the NSRB at Harvard Medical School.
Trypsin sensitivity (content-mixing) assay
This assay was essentially as described previously [24,34].
Liposomes were made with added trypsin at 10 mg/ml.
Unencapsulated trypsin was removed by passage of the suspension
through a Superdex 200 gel filtration column (GE Healthcare).
Small molecules and peptide prepared as DMSO stocks were
diluted into 50 mL of TAN buffer in the presence of purified
virions. Reactions were incubated at 37uC for 15 mins, before the
addition of trypsin-loaded liposomes, acidified with MES pre-
titrated to reach a final pH of 5.5, and incubated at 37uC for
15 mins. Reactions were neutralized to pH 8.0 with 1 M TEA.
Trypsin digestion proceeded for 1 hr at 37uC. Aliquots of the
reaction were resuspended in SDS-loading buffer with 2 mM
PMSF, incubated for 20 mins at 100uC, and analyzed by SDS-
PAGE followed by immunoblotting with an anti-dengue core and
anti-E antibody.
Surface plasmon resonance
Experiments were performed in duplicate on a Biacore 3000
instrument. DI/DII protein was immobilized to a CM5 biosensor
chip per manufacturer’s instructions. All experiments were carried
out at 25 C in HBS-EP buffer (10 mM HEPES, 150 mM NaCl
3 mM EDTA and 0.005% (vol/vol) P20 surfactant). Sensorgrams
were obtained by passing over small molecules diluted in HBS-EP
buffer at specified concentrations at a flow rate of 50 mL/min with
a 2 minute association phase and 10 minute dissociation phase.
The sensor surface was not regenerated between experiments.
Identical injections over blank lanes without protein were used and
subtracted from the data to account for background and
nonspecific interactions with the biosensor chip.
Cells and viruses
C6/36 cells were maintained in L-15 medium supplemented
with 10% fetal bovine serum penicillin and streptomycin
(Invitrogen). For viral plaque assays, BHK-21 cells were seeded
(5610
4cells/well) in 24-well, treated tissue-culture plates in a-
MEM supplemented pen/strep antibiotics, and 5% Fetal Bovine
Serum (FBS). Cells were plated ,12 hrs before use and stored at
37uC with 5% CO2.
Dengue virus serotype 2 New Guinea Clone (NGC) was
adsorbed to confluent layers of C6/36 cells for 1 hr at 25uC with
rocking every 15 mins. L-15 medium (Mediatech) was added, and
cells were incubated at 25uC until syncytium formation was
observed. The supernatant was clarified by centrifugation at
1600 RPM at 4uC and stored at 280uC.
Plaque assay
BHK-21 cells were seeded as described above. Aliquots from
infections were diluted in 10 fold dilutions in Earle’s balanced salt
solution (EBSS), and 100 ml of each dilution were added to cells.
Plates were incubated for 1 hr at 37uC and rocked every 15 mins.
Unadsorbed virus was removed by washing with 1 ml PBS, after
which 1 ml of a-MEM supplemented with 2% carboxymethylcel-
lulose (CMC), pen/strep antibiotics, HEPES and 2% FBS, was
added to each well and incubated at 37uC for 4 days. The CMC
overlay was aspirated, and cells were washed 26with 1 mL PBS
and stained with crystal violet.
Plaque reduction inhibition assays
Virus supernatant was diluted in EBSS to a stock concentration
that would allow for infection at MOI of 1, based on 50,000
seeded cells. Small molecules (or carrier) were added to the
inoculum as indicated for each experiment. Cells were infected for
1h r a t 3 7 uC with gentle rocking every 15 mins. Virus (or
virus:small-molecule mixtures) were washed from cells with 1 mL
of PBS and overlay medium (a-MEM supplemented with HEPES,
pen/strep antibiotics and 2% FBS) added. Plates were incubated
at 37uC for 24 hrs. Aliquots of the supernatant were withdrawn
and stored at 280uC.
Cytotoxicity assay
BHK-21 cells were seeded at a density of 15,000 cells in a 96
well format. Compounds or vehicle were serially diluted in EBSS
and 100 ml were transferred to each well. Plates were incubated at
37uC for 1 hr, media was aspirated and cells were washed 26with
200 ml of PBS. 200 mlo fa-MEM supplemented with pen/strep
antibiotics, and 2% FBS was added and incubated for 24 hrs at
37uC. 20 uL of alamarBlue (Invitrogen) was added directly to each
well and incubate for 2 hrs and read for absorbance at 570 nm.
Supporting Information
Figure S1 Cross-inhibition of dengue serotypes by 1662G07
analogs. (A–D) Inhibition of DV1–4 serotypes by analogs.
(DOC)
Figure S2 Lack of inhibitory activity of 1662G07 analogs
against Kunjin virus infection.
(DOC)
Figure S3 Production and characterization of DI/DII.
(DOC)
Figure S4 Inhibition of sE trimer formation and cofloatation
with liposomes.
(DOC)
Figure S5 Sequence alignment of residues in the b-OG pocket.
(DOC)
Figure S6 In silico docking of small molecules.
(DOC)
Figure S7 The 1662G07 analogs do not inhibit vesicular
stomatitis virus (VSV) infection.
(DOC)
Figure S8 Direct plaque assay of selected compounds from the
3–110 series.
(DOC)
Figure S9 WNV DI/DII does not reverse small-molecule
inhibition of DV2.
(DOC)
Table S1 Broad structure activity relationship of 1662G07.
(DOC)
Dengue-Virus Fusion Inhibitiors
PLoS Pathogens | www.plospathogens.org 9 April 2012 | Volume 8 | Issue 4 | e1002627Table S2 Additional compounds from the 3–149 series.
(DOC)
Table S3 Additional compounds from the 3–110 series.
(DOC)
Text S1 Supplementary methods detailing the synthesis and
characterization of 1662G07 analogs.
(DOC)
Acknowledgments
We thank the NSRB at Harvard Medical School, for use of instrumen-
tation and for advice; Gary Frey and Marco Morelli for assistance with
SPR experiments; Daryl Klein and Robert Corty for help with protein
construct design and production; and members of the Harrison and Yang
laboratories, for helpful discussions.
Author Contributions
Conceived and designed the experiments: AGS SCH. Performed the
experiments: AGS KL. Analyzed the data: AGS KL PLY SCH.
Contributed reagents/materials/analysis tools: KL PLY SCH. Wrote the
paper: AGS KL PLY SCH.
References
1. Harrison SC (2005) Mechanism of membrane fusion by viral envelope proteins.
Adv Virus Res 64: 231–261.
2. Harrison SC (2008) Viral membrane fusion. Nat Struct Mol Biol 15: 690–698.
3. van der Schaar HM, Rust MJ, Chen C, van der Ende-Metselaar H, Wilschut J,
et al. (2008) Dissecting the cell entry pathway of dengue virus by single-particle
tracking in living cells. PLoS Pathog 4: e1000244.
4. van der Schaar HM, Rust MJ, Waarts BL, van der Ende-Metselaar H, Kuhn RJ,
et al. (2007) Characterization of the early events in dengue virus cell entry by
biochemical assays and single-virus tracking. J Virol 81: 12019–12028.
5. Fritz R, Stiasny K, Heinz FX (2008) Identification of specific histidines as pH
sensors in flavivirus membrane fusion. J Cell Biol 183: 353–361.
6. Stiasny K, Fritz R, Pangerl K, Heinz FX (2011) Molecular mechanisms of
flavivirus membrane fusion. Amino Acids 41: 1159–1163.
7. Ferlenghi I, Clarke M, Ruttan T, Allison SL, Schalich J, et al. (2001) Molecular
organization of a recombinant subviral particle from tick-borne encephalitis
virus. Mol Cell 7: 593–602.
8. Bressanelli S, Stiasny K, Allison SL, Stura EA, Duquerroy S, et al. (2004)
Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane
fusion conformation. EMBO J 23: 728–738.
9. Modis Y, Ogata S, Clements D, Harrison SC (2003) A ligand-binding pocket in
the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100:
6986–6991.
10. Modis Y, Ogata S, Clements D, Harrison SC (2005) Variable surface epitopes in
the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79:
1223–1231.
11. Nayak V, Dessau M, Kucera K, Anthony K, Ledizet M, et al. (2009) Crystal
structure of dengue virus type 1 envelope protein in the postfusion conformation
and its implications for membrane fusion. J Virol 83: 4338–4344.
12. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC (1995) The envelope
glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375:
291–298.
13. Allison SL, Schalich J, Stiasny K, Mandl CW, Heinz FX (2001) Mutational
evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol
75: 4268–4275.
14. Kilby JM (1999) Therapeutic potential of blocking HIV entry into cells: focus on
membrane fusion inhibitors. Expert Opin Investig Drugs 8: 1157–1170.
15. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, et al. (1998)
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor
of gp41-mediated virus entry. Nat Med 4: 1302–1307.
16. Wild C, Greenwell T, Matthews T (1993) A synthetic peptide from HIV-1 gp41
is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum
Retroviruses 9: 1051–1053.
17. Wild C, Oas T, McDanal C, Bolognesi D, Matthews T (1992) A synthetic
peptide inhibitor of human immunodeficiency virus replication: correlation
between solution structure and viral inhibition. Proc Natl Acad Sci U S A 89:
10537–10541.
18. Frey G, Rits-Volloch S, Zhang XQ, Schooley RT, Chen B, et al. (2006) Small
molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated
fusion. Proc Natl Acad Sci U S A 103: 13938–13943.
19. Bonfanti JF, Roymans D (2009) Prospects for the development of fusion
inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug
Discov Devel 12: 479–487.
20. Roymans D, De Bondt HL, Arnoult E, Geluykens P, Gevers T, et al. (2010)
Binding of a potent small-molecule inhibitor of six-helix bundle formation
requires interactions with both heptad-repeats of the RSV fusion protein. Proc
Natl Acad Sci U S A 107: 308–313.
21. Liao M, Sanchez-San Martin C, Zheng A, Kielian M (2010) In vitro
reconstitution reveals key intermediate states of trimer formation by the dengue
virus membrane fusion protein. J Virol 84: 5730–5740.
22. Sanchez-San Martin C, Sosa H, Kielian M (2008) A stable prefusion
intermediate of the alphavirus fusion protein reveals critical features of class II
membrane fusion. Cell Host Microbe 4: 600–608.
23. Schmidt AG, Yang PL, Harrison SC (2010) Peptide inhibitors of flavivirus entry
derived from the E protein stem. J Virol 84: 12549–12554.
24. Schmidt AG, Yang PL, Harrison SC (2010) Peptide inhibitors of dengue-virus
entry target a late-stage fusion intermediate. PLoS Pathog 6: e1000851.
25. Modis Y, Ogata S, Clements D, Harrison SC (2004) Structure of the dengue
virus envelope protein after membrane fusion. Nature 427: 313–319.
26. Zhang W, Chipman PR, Corver J, Johnson PR, Zhang Y, et al. (2003)
Visualization of membrane protein domains by cryo-electron microscopy of
dengue virus. Nat Struct Biol 10: 907–912.
27. Kampmann T, Yennamalli R, Campbell P, Stoermer MJ, Fairlie DP, et al.
(2009) In silico screening of small molecule libraries using the dengue virus
envelope E protein has identified compounds with antiviral activity against
multiple flaviviruses. Antiviral Res 84: 234–241.
28. Li Z, Khaliq M, Zhou Z, Post CB, Kuhn RJ, et al. (2008) Design, synthesis, and
biological evaluation of antiviral agents targeting flavivirus envelope proteins.
J Med Chem 51: 4660–4671.
29. Wang QY, Patel SJ, Vangrevelinghe E, Xu HY, Rao R, et al. (2009) A small-
molecule dengue virus entry inhibitor. Antimicrob Agents Chemother 53:
1823–1831.
30. Yennamalli R, Subbarao N, Kampmann T, McGeary RP, Young PR, et al.
(2009) Identification of novel target sites and an inhibitor of the dengue virus E
protein. J Comput Aided Mol Des 23: 333–341.
31. Zhou Z, Khaliq M, Suk JE, Patkar C, Li L, et al. (2008) Antiviral compounds
discovered by virtual screening of small-molecule libraries against dengue virus E
protein. ACS Chem Biol 3: 765–775.
32. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, et al. (2004) Glide:
A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and
Assessment of Docking Accuracy. J Med Chem 47: 1739–1749.
33. Hassaneen H (2007) New Approach to 4- and 5-Aminopyrazole Derivatives.
Synth Commun 37: 3579–3588.
34. Poh MK, Yip A, Zhang S, Priestle JP, Ma NL, et al. (2009) A small molecule
fusion inhibitor of dengue virus. Antiviral Res 84: 260–266.
Dengue-Virus Fusion Inhibitiors
PLoS Pathogens | www.plospathogens.org 10 April 2012 | Volume 8 | Issue 4 | e1002627